[
  {
    "ts": null,
    "headline": "Moderna is the S&P 500's most shorted stock: Here's why",
    "summary": "President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.",
    "url": "https://finnhub.io/api/news?id=074ab3f0f60823d93da8c1893319c62e7dc0649084f6b785072526aaabcf9eaa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764005415,
      "headline": "Moderna is the S&P 500's most shorted stock: Here's why",
      "id": 137591348,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.",
      "url": "https://finnhub.io/api/news?id=074ab3f0f60823d93da8c1893319c62e7dc0649084f6b785072526aaabcf9eaa"
    }
  },
  {
    "ts": null,
    "headline": "Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock",
    "summary": "A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.",
    "url": "https://finnhub.io/api/news?id=2b0351106e5d56c3528387343c5f0c530bc138273a1eab30d887f00ab014f53e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764002785,
      "headline": "Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock",
      "id": 137591351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.",
      "url": "https://finnhub.io/api/news?id=2b0351106e5d56c3528387343c5f0c530bc138273a1eab30d887f00ab014f53e"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer",
    "summary": "Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.",
    "url": "https://finnhub.io/api/news?id=98af2cc2f9a873f458c3b28f9971f784da04a2430e2d118d134cbcf96e09fa8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763999400,
      "headline": "FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer",
      "id": 137591453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.",
      "url": "https://finnhub.io/api/news?id=98af2cc2f9a873f458c3b28f9971f784da04a2430e2d118d134cbcf96e09fa8e"
    }
  },
  {
    "ts": null,
    "headline": "Urinary Tract Infection Treatment Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue",
    "summary": "The Urinary Tract Infection (UTI) Treatment Market is projected to grow from US$ 9.13 Billion in 2024 to US$ 11.64 Billion by 2033, at a CAGR of 2.73%. This expansion is driven by rising UTI prevalence, awareness of early diagnosis, and advancements in therapy. Key growth factors include aging populations, rising catheter-associated infections, and a growing female demographic. Innovative treatments like vaccines and probiotics are gaining traction amid antibiotic resistance. North America leads",
    "url": "https://finnhub.io/api/news?id=0f4d448939a18426431f9da10b2fc6771902e05162ea839762bdf290903530c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763998620,
      "headline": "Urinary Tract Infection Treatment Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue",
      "id": 137591454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Urinary Tract Infection (UTI) Treatment Market is projected to grow from US$ 9.13 Billion in 2024 to US$ 11.64 Billion by 2033, at a CAGR of 2.73%. This expansion is driven by rising UTI prevalence, awareness of early diagnosis, and advancements in therapy. Key growth factors include aging populations, rising catheter-associated infections, and a growing female demographic. Innovative treatments like vaccines and probiotics are gaining traction amid antibiotic resistance. North America leads",
      "url": "https://finnhub.io/api/news?id=0f4d448939a18426431f9da10b2fc6771902e05162ea839762bdf290903530c5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer",
    "summary": "Bayer issued a \"surprisingly positive\" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.",
    "url": "https://finnhub.io/api/news?id=4f3247371cc07420462b1696de3e65534a79240b98fe27e1b197309bd2141cf9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763997966,
      "headline": "Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer",
      "id": 137591535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bayer issued a \"surprisingly positive\" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.",
      "url": "https://finnhub.io/api/news?id=4f3247371cc07420462b1696de3e65534a79240b98fe27e1b197309bd2141cf9"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally",
    "summary": "LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.",
    "url": "https://finnhub.io/api/news?id=3c8c3fead44bf2e2ef33b498d705b3e6657d864f51350c2987919c7fc45ea91f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763990160,
      "headline": "Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally",
      "id": 137591358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.",
      "url": "https://finnhub.io/api/news?id=3c8c3fead44bf2e2ef33b498d705b3e6657d864f51350c2987919c7fc45ea91f"
    }
  },
  {
    "ts": null,
    "headline": "RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum",
    "summary": "RVL Pharmaceuticals, Inc and its affiliates (together, \"RVL\") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.",
    "url": "https://finnhub.io/api/news?id=f92821269aa8017d4bfc71b9f599a27e95fdba175a36f12b6ed7dd1253cbe7db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763988300,
      "headline": "RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum",
      "id": 137589148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "RVL Pharmaceuticals, Inc and its affiliates (together, \"RVL\") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.",
      "url": "https://finnhub.io/api/news?id=f92821269aa8017d4bfc71b9f599a27e95fdba175a36f12b6ed7dd1253cbe7db"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)",
    "summary": "NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is b",
    "url": "https://finnhub.io/api/news?id=cac94449b49f450b6e75f8482768143e8a30ad2e71e0184498768ab31000e6dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763985600,
      "headline": "Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)",
      "id": 137589239,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is b",
      "url": "https://finnhub.io/api/news?id=cac94449b49f450b6e75f8482768143e8a30ad2e71e0184498768ab31000e6dd"
    }
  },
  {
    "ts": null,
    "headline": "What SA Page-View Patterns Of My Articles Reveal About Today's Market - And What Should Investors Do?",
    "summary": "Page-view data shows high engagement for 'hot' stocks regardless of valuation, but considerably less interest in solid and reasonably priced stocks. Read the full analysis now.",
    "url": "https://finnhub.io/api/news?id=fdcc6020f13a1236fb0635beaae0c405357bc88c1cb423ac88d1c7306a540263",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763960310,
      "headline": "What SA Page-View Patterns Of My Articles Reveal About Today's Market - And What Should Investors Do?",
      "id": 137588040,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166346480/image_2166346480.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Page-view data shows high engagement for 'hot' stocks regardless of valuation, but considerably less interest in solid and reasonably priced stocks. Read the full analysis now.",
      "url": "https://finnhub.io/api/news?id=fdcc6020f13a1236fb0635beaae0c405357bc88c1cb423ac88d1c7306a540263"
    }
  }
]